Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lily Tran

Gastroenterology Leesburg, FL Medical Doctor

NPI 1366494874 CMS profile 16481

8110 County Road 44 Leg A, Leesburg, FL 34788

Open in the dashboard

General payments

$11,521

688 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lily Tran of Leesburg, FL is reported in the CMS Open Payments database as having received $11,521 across 688 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,544 109
2024 General $1,967 107
2023 General $1,862 106
2022 General $1,936 123
2021 General $1,607 112
2020 General $716 52
2019 General $888 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lily Tran
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Lily Tran were reported at $2,544. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Lily Tran Gastroenterology median Middle half National median
2019 $888 $417 $126–$1,100 $163
2020 $716 $224 $74–$624 $114
2021 $1,607 $352 $106–$1,054 $132
2022 $1,936 $448 $129–$1,270 $149
2023 $1,862 $533 $150–$1,390 $160
2024 $1,967 $605 $160–$1,606 $164
2025 $2,544 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,956 221 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,775 132 payments
  3. Pfizer Inc. $618 35 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $602 29 payments
  5. Celgene Corporation $475 45 payments
  6. Gilead Sciences, Inc. $436 12 payments
  7. Nestle HealthCare Nutrition Inc. $416 38 payments
  8. Phathom Pharmaceuticals, Inc. $409 25 payments
  9. Aimmune Therapeutics, Inc. $367 18 payments
  10. Madrigal Pharmaceuticals $267 15 payments
  11. Other $2,199 118 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,514 687 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. CREON $1,575 112 payments
  2. LINZESS $1,507 134 payments
  3. XIFAXAN $1,018 66 payments
  4. ZENPEP $783 56 payments
  5. RINVOQ $700 29 payments
  6. XELJANZ $552 29 payments
  7. ZEPOSIA $500 42 payments
  8. ENTYVIO $498 18 payments
  9. TRULANCE $445 32 payments
  10. PLENVU $429 29 payments
  11. Other $5,589 318 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

4,770

Median for Gastroenterology: 569

Drug cost

$1,325,127

Median for Gastroenterology: $104,976

Branded share of claims

12.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gattex Teduglutide Brand 11 $509,932
Creon Lipase/Protease/Amylase Brand 67 $248,260
Zenpep Lipase/Protease/Amylase Brand 22 $133,480
Linzess Linaclotide Brand 68 $91,346
Xifaxan Rifaximin Brand 22 $62,136
Trulance Plecanatide Brand 27 $37,487
Mesalamine Generic 58 $30,999
Dexlansoprazole Dr Dexlansoprazole Brand 77 $28,837
Famotidine Generic 1,315 $25,805
Omeprazole Generic 1,250 $22,120

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$459,713

Medicare's payments for the services billed

Medicare patients

1,292

Average age 75

Services billed

7,516

909 women, 383 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 41%
Chronic kidney disease 33%
Diabetes 29%
Depression 26%
Osteoporosis 24%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CREON
  • AbbVie, Inc. $201
$201 67 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $200
$200 17 —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $184
$184 22 —
SKYRIZI
  • AbbVie, Inc. $183
$183 — —
IBSRELA
  • Ardelyx, Inc. $143
$143 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

688 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record